TICKERNERD
Menu
PROKPROKHealthcare · Biotechnology

PROK Stock Forecast: ProKidney Corp. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.61
0.00% on the day

The 7 Wall Street analysts covering ProKidney Corp. hold a median 12-month price target of $5.75 — +257.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$642.7M
Ticker Nerd rank
26 / 100
Median analyst target
$5.75
Analysts covering
7
Revenue$226K−1.7% y/y
Operating income−$44.9M
Net income−$42.6M
Free cash flow−$45.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+15.0%
1M
+7.3%
YTD
−28.1%
1Y
−33.2%
From 52W high
−51.2%
From 52W low
+21.1%
$1.33
$3.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PROK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ProKidney Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
63
Size
54
Value
54
Revisions
47
Accruals
41
Issuance
36
Momentum
28
Quality
19
Volatility
19

Growth (63): Sales and profits are climbing, and climbing faster than before.

Volatility (19): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PROK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PROK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26PROKHigh $12.00Median $5.75Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
4 Buy2 Hold1 Sell
Low $1.00Median $5.75High $12.00

The green dot is the last close — the median target sits +257.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.ReiteratesBuy$12
16 Dec 2025HC Wainwright & Co.InitiatesBuy—
15 July 2025UBSMaintainsBuy—
14 July 2025GuggenheimMaintainsBuy—
9 July 2025CitigroupMaintainsBuy—
30 June 2025B of A SecuritiesDowngradeUnderperform—
30 Sept 2024JP MorganInitiatesNeutral—
10 Sept 2024GuggenheimInitiatesBuy—
4 Sept 2024B of A SecuritiesMaintainsNeutral—
10 June 2024JefferiesMaintainsBuy—
29 May 2024B of A SecuritiesMaintainsNeutral—
7 Mar 2024Morgan StanleyAssumesEqual-Weight$3.00
2 Jan 2024B of A SecuritiesDowngradeNeutral—
25 July 2023BTIGInitiatesBuy—
21 Dec 2022JefferiesInitiatesBuy—
10 Nov 2022Morgan StanleyInitiatesEqual-Weight—
18 Oct 2022UBSInitiatesBuy—
14 Oct 2022CitigroupInitiatesBuy—
2 Sept 2022Evercore ISI GroupInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PROK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PROK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, ProKidney Corp. returned −33.2% against +19.6% for the S&P 500, dividends included.

PROK vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26PROKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PROK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

ProKidney Corp. (PROK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 87% of US stocks

Price / sales
785.7×

Cheaper than 1% of US stocks

Price / book
0.9×

Cheaper than 78% of US stocks

EV / EBITDA
−7.4×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−32.1%

Higher than 8% of US stocks

Earnings growth (YoY)
−1.7%

Higher than 34% of US stocks

Gross margin
—
Operating margin
−32248.7%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.0%

Higher than 19% of US stocks

Return on assets
−35.7%

Higher than 12% of US stocks

Dividend yield
264.2%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ProKidney Corp. (PROK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ProKidney Corp. has a market value of $642.7M and an enterprise value of $1.3B.

  • Revenue in the twelve months to 31 Mar 2026: $889K. The latest quarter shrank 32.1% year on year.

  • Net income over the same four quarters: −$156.3M, a −17579.4% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$150.1M, after $17.8M of capital spending.

  • Shares outstanding: 142.0M.

  • Trailing P/E: −3.1×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 264.20%, paying out 0% of earnings.

  • ProKidney Corp. employs 231 people — $4K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

PROK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PROKProKidney Corp.$642.7M
26
RLMDRelmada Therapeutics, Inc.$485.6M
68
RZLTRezolute, Inc.$487.1M
37
CCCCC4 Therapeutics, Inc.$492.1M
67
DNAGinkgo Bioworks Holdings, Inc.$479.3M
51
EDITEditas Medicine, Inc.$477.3M
76
QTTBQ32 Bio, Inc.$475.3M
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ProKidney Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PROK news & analysis

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

Seeking Alpha · 14 Aug 2026negative

ProKidney Corp., a single-asset biotech with lead therapy rilparencel, received a rating downgrade from Seeking Alpha. The report cites weak Phase 2 data with confounding factors and no robust efficacy evidence, a cash position of $181.6M with high burn, and a runway extending only into mid-2027 that raises going-concern doubts, with Phase 3 PROACT data in 2027 seen as pivotal.

Why it matters — PROK watchers would care because the item highlights concerns over the company's dwindling cash runway and the uncertain outlook for its only pipeline asset ahead of pivotal Phase 3 data.

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 10 Aug 2026negative

ProKidney Corp. reported a Q2 loss of $0.15 per share, wider than the Zacks Consensus Estimate of a $0.13 loss and the $0.13 loss a year ago. The company also missed revenue estimates.

Why it matters — The quarter came in worse than analyst expectations on both earnings and revenue, signalling a weaker-than-anticipated period for the company.

FAQ

Frequently asked questions about PROK stock

What is the PROK stock price forecast for 2026-2027?

The 7 Wall Street analysts covering ProKidney Corp. have a median 12-month price target of $5.75, with estimates ranging from $1 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PROK stock a buy right now?

Of the 7 analysts covering ProKidney Corp., 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ProKidney Corp. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PROK?

As at 22 Aug 2026, ProKidney Corp. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (63 of 100).

Will PROK stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +257.1% from the last close, and Ticker Nerd's factor model ranks ProKidney Corp. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PROK stock forecast for 2030?

No analyst covering ProKidney Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PROK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $12 over the next 12 months.

How has PROK stock performed over the past year?

ProKidney Corp. returned -33.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ProKidney Corp. do?

ProKidney Corp is a biopharmaceutical company dedicated to pioneering cell therapy solutions for chronic kidney disease (CKD). The company's primary focus is on developing regenerative medicine approaches to address various stages of kidney damage and deterioration.

What is the latest news on PROK?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)". ProKidney Corp., a single-asset biotech with lead therapy rilparencel, received a rating downgrade from Seeking Alpha. The report cites weak Phase 2 data with confounding factors and no robust efficacy evidence, a cash position of $181.6M with high burn, and a runway extending only into mid-2027 that raises going-concern doubts, with Phase 3 PROACT data in 2027 seen as pivotal.

Company

About ProKidney Corp.

ProKidney Corp is a biopharmaceutical company dedicated to pioneering cell therapy solutions for chronic kidney disease (CKD). The company's primary focus is on developing regenerative medicine approaches to address various stages of kidney damage and deterioration. ProKidney's flagship initiative involves the development of REACT (Renal Autologous Cell Therapy), a cutting-edge autologous cell therapy aimed at repairing and regenerating renal tissues. As CKD is a major global health concern, ProKidney Corp's work holds significance in the pharma and healthcare industries, potentially reducing the need for dialysis or kidney transplants. The company impacts the biotechnology sector by introducing innovative solutions designed to improve patient outcomes and lower healthcare costs associated with CKD management. Positioned within the high-stakes environment of medical technology advancements, ProKidney Corp collaborates with healthcare institutions and research organizations to advance its therapies through clinical trials. As the demand for effective chronic disease management solutions grows, ProKidney Corp plays a crucial role in shaping the future of kidney disease treatment by leveraging cutting-edge science to meet unmet medical needs.

CEO Dr. Bruce Culleton M.D. · 231 employees · United States · https://prokidney.com